Table 1 Baseline characteristics. previous treatments and laboratory variables.
From: Impact and consequences of the error of estimated GFR in patients with heart failure
Overall | With Events | Without events | p-value | |
|---|---|---|---|---|
N | 90 | 53 (59) | 37 (41) | |
Age (year) | 66 ± 12 | 67 ± 13 | 65.7 ± 12 | 0.5 |
Gender: men—n (%) | 52 (58) | 34 (64) | 18 (48%) | 0.14 |
Body mass index kg/m2 | 29 ± 5 | 30 ± 5 | 27 ± 5 | 0.01 |
Comorbidities | ||||
Diabetes mellitus—n(%) | 54 (60) | 34 (64) | 20 (54) | 0.33 |
Hypertension—n(%) | 68 (76) | 42 (79) | 26 (70) | 0.33 |
Current smoker—n(%) | 20 (22) | 11 (21) | 9 (24) | 0.7 |
Dyslipidemia—n(%) | 63 (70) | 38 (72) | 25 (68) | 0.67 |
Coronary artery disease—n(%) | 35 (39) | 28 (53) | 7 (19) | 0.001 |
Cerebrovascular diseases—n(%) | 12 (13) | 9 (17) | 3 (8) | 0.23 |
CKD (GFR < 60 mL/min)—n(%) | 31 (34) | 24 (45) | 7 (19) | 0.009 |
Heart failure (HF) | ||||
De novo HF -n(%) | 63 (70) | 31 (58) | 32 (86) | 0.004 |
Previous history of HF | 27 (30) | 22 (37) | 5 (12) | 0.006 |
Etiology of HF | ||||
Ischemic—n(%) | 38 (35) | 30 (59) | 8 (23%) | 0.001 |
Idiopathic—n(%) | 16 (18) | 9 (18) | 7 (21) | 0.73 |
Restrictive—n(%) | 2 (2) | 1 (1) | 1 (3) | 0.77 |
Hypertensive—n(%) | 5 (6%) | 3 (6) | 2 (6) | 1 |
Valvular—n(%) | 24 (27%) | 8 (15) | 16 (47) | 0.002 |
Known duration of HF year | 1.7 (0–30) | 2.7 (0–30) | 0.2 (0–4) | 0.005 |
Left ventricular diameter mm | 57 ± 8 | 59 ± 9 | 55 ± 7 | 0.017 |
E/é ratio | 17 ± 6.5 | 17 ± 6 | 17 ± 6 | 0.54 |
LVOT–VTI cm | 14 ± 5 | 14 ± 5 | 14 ± 4 | 0.90 |
SPAP > 50 mmHg | 18 (20) | 10 (19) | 8 (22) | 0.73 |
LVEF % | 41 ± 14.5 | 38 ± 14 | 43 ± 14 | 0.04 |
Medications | ||||
Aspirin—n(%) | 44 (49) | 30 (57) | 14 (38) | 0.08 |
ACEi/ARAii—n(%) | 52 (61) | 32 (61) | 20 (38) | 0.34 |
Betablockers—n(%) | 54 (60) | 34 (64) | 20 (54) | 0.34 |
Furosemide—n(%) | 52 (58) | 40 (75) | 12 (32) | < 0.0001 |
Statins (n-%) | 60 (67) | 41 (77) | 19 (51) | 0.10 |
Mineralocorticoid receptor antagonists (n-%) | 21 (24) | 17 (33) | 4 (11) | 0.02 |
Laboratory | ||||
Hemoglobin gr/dL | 12 ± 2 | 12 ± 2 | 12.8 ± 2 | 0.09 |
HbA1c % | 6.9 ± 1.8 | 7.1 ± 1.9 | 6.5 ± 1.5 | 0.14 |
Triglycerides mg/dL | 119 ± 50 | 118 ± 50 | 121 ± 49 | 0.77 |
LDL-cholesterol mg/dL | 78 ± 34 | 65 ± 28 | 95 ± 32 | 0.0001 |
Troponin T us pg/mL | 208 ± 353 | 245 ± 372 | 156 ± 321 | 0.25 |
NT-proBNP pg/mL | 8745 ± 8349 | 8238 ± 7949 | 9470 ± 8954 | 0.45 |
Heart Rate bpm | 97 ± 23 | 92 ± 18 | 106 ± 26 | 0.002 |
Systolic BP mmHg | 132 ± 29 | 127 ± 25 | 139 ± 32 | 0.06 |
Diastolic BP mmHg | 75 ± 16.4 | 72 ± 13 | 78 ± 20 | 0.06 |
Follow-up time year | 3 ± 2 | 2 ± 2 | 4 ± 1.5 | p < 0.001 |
